Last reviewed · How we verify
NCT04591821
Bowel Dysfunction 3 Years After Anterior Resection a in a Swedish National Cohort
trial in Low Anterior Resection Syndrome in 1,200 participants. Completed in 15 November 2020.
15 September 2020
Quick facts
| Lead sponsor | Region Skane |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,200 |
| Start date | 15 February 2018 |
| Primary completion | 15 September 2020 |
| Estimated completion | 15 November 2020 |
| Sites | 1 location across Sweden |
Conditions studied
- Low Anterior Resection Syndrome — all drugs for Low Anterior Resection Syndrome →
- Rectal Cancer — all drugs for Rectal Cancer →
Sponsor
Region Skane — full company profile →
Who can join
18 and older, any sex, with Low Anterior Resection Syndrome or Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objectives are to evaluate the prevalence of LARS and Quality of Life in rectal cancer patients 3 years after anterior resection, to investigate if anastomotic technique is a risk factor for major LARS and to study the prevalence of colostomy 3 years after anterior resection and evaluate stoma function according to the stoma scale in EORTC QLQ-CR29.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04591821
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Low Anterior Resection Syndrome
Currently open trials in the same condition.
- NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
- NCT06424522 — A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Canc · NA · recruiting
- NCT06758830 — Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. · Phase 2, PHASE3 · recruiting
- NCT06724198 — Bowel Dysfunction After Low Rectal Resection. An Pilot Study Using Psyllium Husk In Rectal Cancer Patients. · NA · active not recruiting
- NCT06222255 — The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome · NA · recruiting
Other Region Skane trials
Trials by the same sponsor.
- NCT07511673 — The Study is a Randomised Clinical Trial (RCT) to Test if Preoperative Dental Screening is Superior to no Preoperative D · NA · not yet recruiting
- NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
- NCT07494669 — Proteomics and Physiological Parameters Predicting Complications After Colorectal Cancer Surgery · not yet recruiting
- NCT07462351 — System-integrated Point-of-Care Ultrasound in Breast Cancer Screening · NA · recruiting
- NCT06975696 — Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04591821 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Skane
- Last refreshed: 18 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04591821.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing